By Colin Kellaher
Shares of Asensus Surgical Inc. rose more than 10% on Monday after the medical-device company said the U.S. Food and Drug Administration approval for the expanded use of its Senhance System to treat pediatric patients.
The Durham, N.C., company said it has seen strong early clinical use in Europe, where the system is already approved for pediatric patients.
The FDA first approved the Senhance System, robotically-assisted surgical device for minimally invasive surgery, for use in adults in 2017.
Asensus shares were recently changing hands at 67 cents, up about 10%.
Write to Colin Kellaher at email@example.com
(END) Dow Jones Newswires
March 20, 2023 10:12 ET (14:12 GMT)Copyright (c) 2023 Dow Jones & Company, Inc.